Abbott Laboratories Financial Statements
NYSE: ABTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:02 PM ET · Delayed 15 min
Abbott Laboratories revenue and earnings
In fiscal 2025, Abbott Laboratories generated $44.33 billion in revenue, up 5.7% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $6.52 billion (-51.3% year over year), for a net margin of 14.7% versus a median of 15.9% in the prior 5 years. Gross margin was 56.4% (up from 55.4%) and operating margin 18.2%.
Diluted earnings per share came in at $3.72, down from $7.64. Over the last 5 fiscal years, ABT's revenue has grown at a 5.1% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Abbott Laboratories income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 44.33B | 41.95B | 40.11B | 43.65B | 43.08B | 34.61B | 31.90B | 30.58B | 27.39B | 20.85B |
| Revenue growth (YoY) | +5.67% | +4.59% | -8.12% | +1.34% | +24.47% | +8.48% | +4.34% | +11.64% | +31.35% | +2.20% |
| Cost of Revenue | 19.32B | 18.71B | 17.98B | 19.14B | 18.54B | 15.00B | 13.23B | 12.71B | 12.41B | 9.09B |
| Gross Profit | 25.01B | 23.24B | 22.13B | 24.51B | 24.54B | 19.61B | 18.67B | 17.87B | 14.98B | 11.76B |
| Operating Expenses | 16.96B | 16.42B | 15.66B | 16.15B | 16.11B | 14.25B | 14.14B | 14.22B | 13.42B | 8.73B |
| Research & Development | 2.94B | 2.84B | 2.74B | 2.89B | 2.74B | 2.42B | 2.44B | 2.30B | 2.26B | 1.45B |
| Selling, General & Admin | 12.33B | 11.70B | 10.95B | 11.25B | 11.32B | 9.70B | 9.77B | 9.74B | 9.18B | 6.74B |
| Operating Income | 8.05B | 6.83B | 6.48B | 8.36B | 8.43B | 5.36B | 4.53B | 3.65B | 1.56B | 3.03B |
| Interest Expense | 493.00M | 559.00M | 637.00M | 558.00M | 533.00M | 546.00M | 670.00M | 826.00M | 904.00M | 431.00M |
| Other Income (Expense) | 548.00M | 376.00M | 479.00M | 321.00M | 277.00M | 103.00M | 191.00M | 139.00M | 1.41B | -786.00M |
| Pretax Income | 8.47B | 7.01B | 6.66B | 8.31B | 8.21B | 4.97B | 4.08B | 2.87B | 2.23B | 1.41B |
| Income Tax | 1.94B | -6.39B | 941.00M | 1.37B | 1.14B | 497.00M | 390.00M | 539.00M | 1.88B | 350.00M |
| Net Income | 6.52B | 13.40B | 5.72B | 6.93B | 7.07B | 4.50B | 3.69B | 2.37B | 477.00M | 1.40B |
| Net Income growth (YoY) | -51.32% | +134.18% | -17.45% | -1.95% | +57.31% | +21.91% | +55.70% | +396.44% | -65.93% | -68.35% |
| EPS (Basic) | 3.73 | 7.67 | 3.28 | 3.94 | 3.97 | 2.52 | 2.07 | 1.34 | 0.27 | 0.94 |
| EPS (Diluted) | 3.72 | 7.64 | 3.26 | 3.91 | 3.94 | 2.50 | 2.06 | 1.33 | 0.27 | 0.94 |
| Shares Outstanding (Basic) | 1.74B | 1.74B | 1.74B | 1.75B | 1.77B | 1.77B | 1.77B | 1.76B | 1.74B | 1.48B |
| Shares Outstanding (Diluted) | 1.75B | 1.75B | 1.75B | 1.76B | 1.79B | 1.79B | 1.78B | 1.77B | 1.75B | 1.48B |
| EBITDA | 9.49B | 8.16B | 7.75B | 9.62B | 9.92B | 6.55B | 5.61B | 4.75B | 2.61B | 3.83B |
| Gross Margin | 56.42% | 55.41% | 55.18% | 56.15% | 56.97% | 56.65% | 58.53% | 58.45% | 54.70% | 56.39% |
| Operating Margin | 18.17% | 16.27% | 16.15% | 19.16% | 19.56% | 15.48% | 14.21% | 11.94% | 5.71% | 14.51% |
| Net Margin | 14.72% | 31.95% | 14.27% | 15.88% | 16.42% | 12.99% | 11.56% | 7.74% | 1.74% | 6.71% |
This table shows 10 annual periods of Abbott Laboratories's income statement, from FY 2025 back to FY 2016, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow ABT's reporting calendar. What is a income statement?